Clinical Development Update from Portfolio Company LogicBio
Retrieved on:
Monday, May 9, 2022
Capsid, Generides, Homologous recombination, IND, Nasdaq, SUNRISE, EMA, Mouse, European Medicines Agency, Biotechnology, Genome, AAV, Food, Methylmalonic acidemia, Safety, Time, Patient, Review, Survival, Methylmalonyl-CoA, FDA, Letter, Hepatocyte, Cancer, Industry, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DNA, Lifting, Tissue, Thrombotic microangiopathy, Methylmalonyl-CoA mutase, List of life sciences, Liver, TMA, Time-invariant system, Growth, Risk, Therapy, Pharmaceutical industry, Vaccine, MMA
As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
Key Points:
- As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
- In its letter, the FDA acknowledged that the company satisfactorily addressed all clinical hold issues.
- In connection with the lifting of the clinical hold, LogicBio amended the SUNRISE protocol in a manner that reflected its dialogue with the FDA.
- LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood.